As the Food and Drug Administration (FDA) begins to deemphasize the interchangeability designation, with an eye towards making any approved biosimilar interchangeable with the reference product, an expert panel at this week’s GRx+Biosims 2024 conference tackled the prevailing issue: Does interchangeability matter today? One major detail underlying this discussion was not specifically mentioned: An interchangeability … Continue reading Practically Speaking, Does Biosimilar Interchangeability Matter Today?